Cargando…

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit

The frequent alterations of the PI3K/Akt/mTOR-growth signaling pathway are proposed mechanisms for resistance to endocrine therapy in breast cancer, partly through regulation of estrogen receptor α (ER) activity. Reliable biomarkers for treatment prediction are required for improved individualized t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bostner, Josefine, Karlsson, Elin, Pandiyan, Muneeswaran J., Westman, Hanna, Skoog, Lambert, Fornander, Tommy, Nordenskjöld, Bo, Stål, Olle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2012
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539073/ https://www.ncbi.nlm.nih.gov/pubmed/23242584 http://dx.doi.org/10.1007/s10549-012-2376-y

Ejemplares similares

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials
por: Karlsson, Elin, et al.
Publicado: (2013)

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
por: Hilborn, Erik, et al.
Publicado: (2014)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
por: Nordenskjöld, Anna, et al.
Publicado: (2016)

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
por: Jerevall, Piiha-Lotta, et al.
Publicado: (2010)

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer
por: Sivik, Tove, et al.
Publicado: (2012)

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer
por: Karlsson, Elin, et al.
Publicado: (2018)

Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis
por: Karlsson, Elin, et al.
Publicado: (2015)

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
por: Hilborn, Erik, et al.
Publicado: (2016)

Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial
por: Dar, Huma, et al.
Publicado: (2021)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
por: Weiner, M., et al.
Publicado: (2013)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype
por: Veenstra, Cynthia, et al.
Publicado: (2019)

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk
por: van ‘t Veer, Laura J., et al.
Publicado: (2017)

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
por: Nordenskjöld, Anna, et al.
Publicado: (2023)

IP6K2 predicts favorable clinical outcome of primary breast cancer
por: Sandström, Josefine, et al.
Publicado: (2021)

Combination treatment of cancer cells with pan-Akt and pan-mTOR inhibitors: effects on cell cycle distribution, p-Akt expression level and radiolabelled-choline incorporation
por: Phyu, Su Myat, et al.
Publicado: (2018)

Akt kinases in breast cancer and the results of adjuvant therapy
por: Stål, Olle, et al.
Publicado: (2003)

PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway
por: Xing, Xiaofang, et al.
Publicado: (2014)

High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer
por: Paulsson, Janna, et al.
Publicado: (2016)

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
por: He, Jichao, et al.
Publicado: (2019)

Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro
por: Trendowski, Matthew, et al.
Publicado: (2015)

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
por: Rosell, J, et al.
Publicado: (2011)

Met and its ligand HGF are associated with clinical outcome in breast cancer
por: Veenstra, Cynthia, et al.
Publicado: (2016)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
por: Schroeder, Brock, et al.
Publicado: (2017)

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature
por: Johansson, Annelie, et al.
Publicado: (2022)

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
por: Wander, Seth A., et al.
Publicado: (2013)

PBI-05204, a supercritical CO(2) extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway
por: Pan, Yong, et al.
Publicado: (2014)

Expression of Akt kinases related to ErbB2 and results of adjuvant therapy of breast cancer
por: Stal, O, et al.
Publicado: (2000)

Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells
por: Kim, Seung-Su, et al.
Publicado: (2020)

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
por: Wegman, Pia, et al.
Publicado: (2007)

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics
por: Groenendijk, Floris H., et al.
Publicado: (2013)

Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor-α activity on breast metabolic signaling
por: Arnone, Alana A., et al.
Publicado: (2021)

Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells
por: Leung, Euphemia, et al.
Publicado: (2011)

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit
por: Løkkegaard, Sanne, et al.
Publicado: (2021)

The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

Luminal Breast Cancer Cell Lines Overexpressing ZNF703 Are Resistant to Tamoxifen through Activation of Akt/mTOR Signaling
por: Zhang, Xi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_26gh9qc39s0sgltlqvrl1o38ub